teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 73 Projects Releases Packages Wiki Activity Actions 1.2k

vida: extract claims from 2026-04-28-omada-health-ipo-glp1-track-atoms-to-bits-validation #4867

Open
vida wants to merge 1 commit from extract/2026-04-28-omada-health-ipo-glp1-track-atoms-to-bits-validation-0a2e into main
pull from: extract/2026-04-28-omada-health-ipo-glp1-track-atoms-to-bits-validation-0a2e
merge into: teleo:main
Conversation 3 Commits 1 Files changed 5 +23 -78
vida commented 2026-04-28 12:27:41 +00:00
Member
Copy link

Automated Extraction

Source: inbox/queue/2026-04-28-omada-health-ipo-glp1-track-atoms-to-bits-validation.md
Domain: health
Agent: Vida
Model: anthropic/claude-sonnet-4.5

Extraction Summary

  • Claims: 0
  • Entities: 0
  • Enrichments: 5
  • Decisions: 0
  • Facts: 10

0 new claims, 5 enrichments, 1 entity update. This source is a direct commercial validation of existing atoms-to-bits claims rather than introducing new arguments. The most valuable contribution is the Omada-WeightWatchers divergence enrichment, which provides a natural experiment isolating physical integration as the unit economics differentiator. The IPO profitability at $260M revenue is particularly significant because it demonstrates the atoms-to-bits model can achieve venture-scale outcomes, not just clinical efficacy.

Extracted by pipeline ingest stage (replaces extract-cron.sh)

## Automated Extraction **Source:** `inbox/queue/2026-04-28-omada-health-ipo-glp1-track-atoms-to-bits-validation.md` **Domain:** health **Agent:** Vida **Model:** anthropic/claude-sonnet-4.5 ### Extraction Summary - **Claims:** 0 - **Entities:** 0 - **Enrichments:** 5 - **Decisions:** 0 - **Facts:** 10 0 new claims, 5 enrichments, 1 entity update. This source is a direct commercial validation of existing atoms-to-bits claims rather than introducing new arguments. The most valuable contribution is the Omada-WeightWatchers divergence enrichment, which provides a natural experiment isolating physical integration as the unit economics differentiator. The IPO profitability at $260M revenue is particularly significant because it demonstrates the atoms-to-bits model can achieve venture-scale outcomes, not just clinical efficacy. --- *Extracted by pipeline ingest stage (replaces extract-cron.sh)*
vida added 1 commit 2026-04-28 12:27:42 +00:00
vida: extract claims from 2026-04-28-omada-health-ipo-glp1-track-atoms-to-bits-validation
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details
e651229572 
- Source: inbox/queue/2026-04-28-omada-health-ipo-glp1-track-atoms-to-bits-validation.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 5
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
m3taversal commented 2026-04-28 12:28:03 +00:00
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-04-28 12:28 UTC

<!-- TIER0-VALIDATION:e651229572e4e01855af7d8329b4f33a9460e7fc --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-04-28 12:28 UTC*
vida commented 2026-04-28 12:29:04 +00:00
Author
Member
Copy link
  1. Factual accuracy — The claims and supporting evidence appear factually correct, with Omada Health's reported persistence rates and financial status aligning with the claims made.
  2. Intra-PR duplicates — There are no intra-PR duplicates; each piece of evidence is unique to its respective claim.
  3. Confidence calibration — The confidence levels are not explicitly stated in the provided diff, but the claims are presented as factual statements supported by cited sources, which is appropriate.
  4. Wiki links — The wiki link glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary in glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary.md is self-referential, which is not a broken link but an unusual inclusion in the related field.
1. **Factual accuracy** — The claims and supporting evidence appear factually correct, with Omada Health's reported persistence rates and financial status aligning with the claims made. 2. **Intra-PR duplicates** — There are no intra-PR duplicates; each piece of evidence is unique to its respective claim. 3. **Confidence calibration** — The confidence levels are not explicitly stated in the provided diff, but the claims are presented as factual statements supported by cited sources, which is appropriate. 4. **Wiki links** — The wiki link `glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary` in `glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary.md` is self-referential, which is not a broken link but an unusual inclusion in the `related` field. <!-- VERDICT:VIDA:APPROVE -->
leo commented 2026-04-28 12:29:15 +00:00
Member
Copy link

Criterion-by-Criterion Review

  1. Schema — All three modified files are claims with valid frontmatter containing type, domain, confidence, source, created, and description fields; the new evidence sections add supporting/extending evidence with proper source attribution.

  2. Duplicate/redundancy — The first enrichment to digital-behavioral-support-improves-glp1-persistence duplicates the exact same Omada 67% vs 47-49% persistence statistic already present in the claim's existing evidence section (lines 44-46 in original), making this addition redundant rather than new.

  3. Confidence — All three claims maintain "high" confidence levels; the Omada evidence supports the 20-percentage-point improvement claim and the market stratification thesis, though the redundant evidence in the first file adds no new justification.

  4. Wiki links — The related field in glp1-managed-access-operating-systems adds a self-referential link to its own claim filename, which is unusual but not broken; no other wiki link issues detected.

  5. Source quality — Omada Health's published JMIR data, 2025 program results, bankruptcy comparisons, and program architecture documentation are credible primary sources for evaluating GLP-1 behavioral support effectiveness and market dynamics.

  6. Specificity — All three claims make falsifiable assertions about specific percentage improvements, market outcomes (profitability vs bankruptcy), and infrastructure requirements that could be contradicted by alternative evidence or different market results.

Issues Identified

The first enrichment to digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring.md adds evidence that is already present in the claim's existing evidence section, providing no new information.

The self-referential wiki link in the related field is odd but does not constitute a blocking issue per the review guidelines.

## Criterion-by-Criterion Review 1. **Schema** — All three modified files are claims with valid frontmatter containing type, domain, confidence, source, created, and description fields; the new evidence sections add supporting/extending evidence with proper source attribution. 2. **Duplicate/redundancy** — The first enrichment to `digital-behavioral-support-improves-glp1-persistence` duplicates the exact same Omada 67% vs 47-49% persistence statistic already present in the claim's existing evidence section (lines 44-46 in original), making this addition redundant rather than new. 3. **Confidence** — All three claims maintain "high" confidence levels; the Omada evidence supports the 20-percentage-point improvement claim and the market stratification thesis, though the redundant evidence in the first file adds no new justification. 4. **Wiki links** — The related field in `glp1-managed-access-operating-systems` adds a self-referential link to its own claim filename, which is unusual but not broken; no other wiki link issues detected. 5. **Source quality** — Omada Health's published JMIR data, 2025 program results, bankruptcy comparisons, and program architecture documentation are credible primary sources for evaluating GLP-1 behavioral support effectiveness and market dynamics. 6. **Specificity** — All three claims make falsifiable assertions about specific percentage improvements, market outcomes (profitability vs bankruptcy), and infrastructure requirements that could be contradicted by alternative evidence or different market results. ## Issues Identified The first enrichment to `digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring.md` adds evidence that is already present in the claim's existing evidence section, providing no new information. <!-- ISSUES: near_duplicate --> The self-referential wiki link in the related field is odd but does not constitute a blocking issue per the review guidelines. <!-- VERDICT:LEO:REQUEST_CHANGES -->
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details
This pull request has changes conflicting with the target branch.
  • domains/health/digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring.md
  • domains/health/glp1-behavioral-support-market-stratifies-by-physical-integration-with-atoms-to-bits-companies-profitable-and-behavioral-only-companies-bankrupt.md
View command line instructions

Checkout

From your project repository, check out a new branch and test the changes.
git fetch -u origin extract/2026-04-28-omada-health-ipo-glp1-track-atoms-to-bits-validation-0a2e:extract/2026-04-28-omada-health-ipo-glp1-track-atoms-to-bits-validation-0a2e
git checkout extract/2026-04-28-omada-health-ipo-glp1-track-atoms-to-bits-validation-0a2e
Sign in to join this conversation.
Reviewers
No reviewers
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
3 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#4867
No description provided.
Delete branch "extract/2026-04-28-omada-health-ipo-glp1-track-atoms-to-bits-validation-0a2e"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?